Finanzas de Park Ha Biological Technology Co Ltd (BYAH)BYAHPark Ha Biological Technology Co Ltd

Evaluating the bottom line, Park Ha Biological Technology Co Ltd maintains a gross margin of 96.36%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -76.53%, while the net margin is -73.01%. These profitability ratios, combined with a Return on Equity (ROE) of -113.04%, provide a clear picture of how effectively BYAH converts its operational activities into shareholder value.

In the context of the broader market, BYAH competes directly with industry leaders such as DRMA and NHTC. With a market capitalization of $8.53M, it holds a leading position in the sector. When comparing efficiency, BYAH's gross margin of 96.36% stands against DRMA's N/A and NHTC's 75.10%. Such benchmarking helps identify whether Park Ha Biological Technology Co Ltd is trading at a premium or discount relative to its financial performance.

The financial performance shows a negative P/E ratio of -5.71 and a forward P/E of 0, indicating a lack of profitability and uncertainty about future earnings. The price-to-sales ratio is 18.33, which is quite high, suggesting that the stock may be overvalued relative to its sales.